Overcoming the exacerbating effects of ranitidine on NSAID-induced small intestinal toxicity with quercetin: Providing a complete GI solution

Chemico-Biological Interactions

Volumn 272, Issue , 2017, Pages 53-64

  Singh, Devendra Pratap ^a,b   Borse, Swapnil P ^a,b   Nivsarkar, Manish ^a  

^a B V PATEL PHARMACEUTICAL EDUCATION AND RESEARCH DEVELOPMENT PERD CENTRE   (India)

^b NIRMA UNIVERSITY   (India)

Author keywords

Gastroenteropathy; Nonsteroidal anti inflammatory drugs; Permeability; Quercetin; Ranitidine; Ulcers

Indexed keywords

ALBUMIN; NONSTEROID ANTIINFLAMMATORY AGENT; QUERCETIN; RANITIDINE; XANTHINE OXIDASE; DICLOFENAC; MALONALDEHYDE; REACTIVE OXYGEN METABOLITE;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FOOD INTAKE; GASTROINTESTINAL TOXICITY; INTESTINE MUCOSA PERMEABILITY; LIPID PEROXIDATION; MALE; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PH; PROTEIN DEPLETION; RAT; SMALL INTESTINAL TOXICITY; STOMACH INJURY; WEIGHT CHANGE; ANIMAL; BODY WEIGHT; CHEMICALLY INDUCED; DRUG EFFECTS; EATING; GASTROINTESTINAL DISEASES; METABOLISM; PATHOLOGY; PERMEABILITY; SMALL INTESTINE; STOMACH; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY WEIGHT; DICLOFENAC; EATING; GASTROINTESTINAL DISEASES; INTESTINE, SMALL; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PERMEABILITY; QUERCETIN; RANITIDINE; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; STOMACH; XANTHINE OXIDASE;

EID: 85019927454     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2017.04.006     Document Type: Article

References (131)

1. Wallace, J.L., Prevention of NSAID-enteropathy: a soluble problem?. Dig. Dis. Sci. 61:1 (2016), 1–3.
2. Singh, D.P., Borse, S.P., Nivsarkar, M., Clinical importance of nonsteroidal anti-inflammatory drug enteropathy: the relevance of tumor necrosis factor as a promising target. Transl. Res. 175 (2016), 76–91.
3. Satoh, H., Amagase, K., Takeuchi, K., Mucosal protective agents prevent exacerbation of NSAID-induced small intestinal lesions caused by antisecretory drugs in rats. J. Pharmacol. Exp. Ther. 348:2 (2014), 227–235.
4. Wallace, J.L., et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 141:4 (2011), 1314–1322 e5.
5. Satoh, H., Amagase, K., Takeuchi, K., Exacerbation of nonsteroidal anti-inflammatory drug-induced small intestinal lesions by antisecretory drugs in rats: the role of intestinal motility. J. Pharmacol. Exp. Ther. 343:2 (2012), 270–277.
6. Singh, D.P., Borse, S.P., Nivsarkar, M., A novel model for NSAID induced gastroenteropathy in rats. J. Pharmacol. Toxicol. Methods 78 (2016), 66–75.
7. Lanas, A., et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am. J. Gastroenterol. 104:7 (2009), 1633–1641.
8. Wallace, J.L., Polypharmacy of osteoarthritis: the perfect intestinal storm. Dig. Dis. Sci. 58:11 (2013), 3088–3093.
9. Wallace, J.L., NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. Br. J. Pharmacol. 165:1 (2012), 67–74.
10. Bjarnason, I., Takeuchi, K., Intestinal permeability in the pathogenesis of NSAID-induced enteropathy. J. Gastroenterology 44:19 (2009), 23–29.
11. Blackler, R.W., et al. NSAID-gastroenteropathy: new aspects of pathogenesis and prevention. Curr. Opin. Pharmacol. 19 (2014), 11–16.
12. Singh, D.P., Borse, S.P., Nivsarkar, M., A novel model for NSAID induced gastroenteropathy in rats. J. Pharmacol. Toxicol. Methods 78 (2016), 66–75.
13. Roy, A., Patwardhan, B., Chaguturu, R., Reigniting pharmaceutical innovation through holistic drug targeting. Drug Discov. World, Summer, 2016, 45–55.
14. Patwardhan, B., Ethnopharmacology and drug discovery. J. Ethnopharmacol. 100:1 (2005), 50–52.
15. Patwardhan, B., Vaidya, A.D., Natural Products Drug Discovery: Accelerating the Clinical Candidate Development Using Reverse Pharmacology Approaches. 2010.
16. Novaes, R.D., Leite, J.P.V., Ethnopharmacology as current strategy in the search of novel anti-ulcerogenic drugs: case of a Brazilian medicinal plant (Maytenus ilicifolia Mart. ex. Reissek). Peptic Ulcer Dis., 2011, 375.
17. Haastrup, P., et al. Rapidly increasing prescribing of proton pump inhibitors in primary care despite interventions: a nationwide observational study. Eur. J. Gen. Pract. 20:4 (2014), 290–293.
18. Thomas, J., Straus, W.L., Bloom, B.S., Over-the-counter nonsteroidal anti-inflammatory drugs and risk of gastrointestinal symptoms. Am. J. Gastroenterol. 97:9 (2002), 2215–2219.
19. Gupta, S.C., Patchva, S., Aggarwal, B.B., Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 15:1 (2013), 195–218.
20. Kawabata, K., Mukai, R., Ishisaka, A., Quercetin and related polyphenols: new insights and implications for their bioactivity and bioavailability. Food & Funct. 6:5 (2015), 1399–1417.
21. Surh, Y.-J., Reverse pharmacology applicable for Botanical drug development–inspiration from the legacy of traditional wisdom. J. Trad. Complem Med. 2011:1 (2011), 5–7.
22. Akhtar, M.S., Munir, M., Evaluation op the gastric antiulcerogenic effects of Solanum nigrum, Brassica oleracea and Ocimum basilicum in rats. J. Ethnopharmacol. 27:1 (1989), 163–176.
23. Harvey, A.L., Natural products in drug discovery. Drug Discov. today 13:19 (2008), 894–901.
24. Harwood, M., et al. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem. Toxicol. 45:11 (2007), 2179–2205.
25. Gohar, A.A., Zaki, A.A., Assessment of some herbal drugs for prophylaxis of peptic ulcer. Iran. J. Pharm. Res. IJPR, 13(3), 2014, 1081.
26. Miean, K.H., Mohamed, S., Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J. Agric. Food Chem. 49:6 (2001), 3106–3112.
27. Carvalho, C.A.d., et al. Evaluation of antiulcerogenic activity of aqueous extract of Brassica oleracea var. capitata (cabbage) on Wistar rat gastric ulceration. Arq. Gastroenterol. 48:4 (2011), 276–282.
28. Lemos, M., et al. Gastroprotective activity of hydroalcoholic extract obtained from the leaves of Brassica oleracea var. acephala DC in different animal models. J. Ethnopharmacol. 138:2 (2011), 503–507.
29. Kang, J., et al. Effect of capsaicin and chilli on ethanol induced gastric mucosal injury in the rat. Gut 36:5 (1995), 664–669.
30. Borrelli, F., Izzo, A.A., The plant kingdom as a source of anti-ulcer remedies. Phytotherapy Res. 14:8 (2000), 581–591.
31. Bastaki, S., et al. Comparative effect of garlic (Allium sativum), onion (Allium cepa), and black seed (Nigella sativa) on gastric acid secretion and gastric ulcer. Res. Rep. Med. Chem. 1 (2011), 3–9.
32. Alqasoumi, S., The Use of Onion (Allium cepa L.) Treatment Can Mitigate Gastric Mucosal Injury in Rats. 2015.
33. Azamthulla, M., Asad, M., Prasad, V.S., Antiulcer activity of Allium sativum bulb juice in rats. Saudi Pharm. J. 17:1 (2009), 70–77.
34. Oloyede, H.O., et al. Anti-ulcerogenic activity of aqueous extract of Carica papaya seed on indomethacin-induced peptic ulcer in male albino rats. J. Integr. Med. 13:2 (2015), 105–114.
35. Ezike, A., et al. Carica papaya (Paw-Paw) unripe fruit may be beneficial in ulcer. J. Med. food 12:6 (2009), 1268–1273.
36. Gürbüz, I., et al. Anti-ulcerogenic activity of some plants used as folk remedy in Turkey. J. Ethnopharmacol. 88:1 (2003), 93–97.
37. Jayaraj, A., Tovey, F., Clark, C., Possible dietary protective factors in relation to the distribution of duodenal ulcer in India and Bangladesh. Gut 21:12 (1980), 1068–1076.
38. Okasha, M., et al. Study of the effect of Hibiscus esculentus Linn (Okra) extract on indomethacin-induced gastric mucosal damage and gastric secretion in rats. Nat. Sci., 12(12), 2014.
39. Vimala, G., Gricilda Shoba, F., A review on antiulcer activity of few Indian medicinal plants. Int. J. Microbiol., 2014, 2014.
40. Konan, N.A., Bacchi, E.M., Antiulcerogenic effect and acute toxicity of a hydroethanolic extract from the cashew (Anacardium occidentale L.) leaves. J. Ethnopharmacol. 112:2 (2007), 237–242.
41. Maity, S., et al. Cytoprotection mediated antiulcer effect of tea root extract. Indian J. Pharmacol. 35:4 (2003), 213–219.
42. Das, S., Dutta, S., Deka, S., A study of the anti-ulcer activity of the ethanolic extract of the leaves of Psidium guajava on experimental animal models. Internet J. Pharmacol.(1), 2009, 7.
43. Kumar, A.P., et al. Pharmacognostical, phytochemical and pharmacological evaluation for the antiulcer activity of polyherbal suspension. J. Pharmacogn. Phytochemistry(3), 2013, 2.
44. Choudhary, M.K., Bodakhe, S.H., Gupta, S.K., Assessment of the antiulcer potential of Moringa oleifera root-bark extract in rats. J. Acupunct. Meridian Stud. 6:4 (2013), 214–220.
45. Devaraj, V., Asad, M., Prasad, S., Effect of leaves and fruits of Moringa oleifera. on gastric and duodenal ulcers. Pharm. Biol. 45:4 (2007), 332–338.
46. Alrawaiq, N.S., Abdullah, A., A review of flavonoid quercetin: metabolism, bioactivity and antioxidant properties. Int. J. PharmTech Res. 6:3 (2014), 933–941.
47. Singh, D.P., Borse, S.P., Nivsarkar, M., Clinical importance of nonsteroidal antiinflammatory drug enteropathy: the relevance of tumor necrosis factor as a promising target. Transl. Res. 175 (2016), 76–91.
48. Devendra Pratap Singh S.P.B., Manish Nivsarkar, A Novel Model for NSAID Induced Gastroenteropathy and the Proposed Role of TNF-α: Way Forward for the Discovery of Futuristic Therapeutic Interventions, in 3rd Nirma Institute of Pharmacy International Conference-NIPiCON 2016 “Global Challenges in Drug Discovery, Development and Regulatory affairs”. 2016: Ahmedabad, http://dx.doi.org/10.13140/RG.2.1.3147.9445.
49. Singh, D.P., Borse, S.P., Nivsarkar, M., Co-administration of quercetin with pantoprazole sodium prevents NSAID-induced severe gastroenteropathic damage efficiently: evidence from a preclinical study in rats. Exp. Toxicol. Pathology 69:1 (2017), 17–26.
50. Devendra Pratap Singh, S.P.B., Niivsarkar, Manish, Unravelling a novel therapeutic strategy for the management of NSAID-induced gastroenteropathy: addressing an unannounced emergency. 49th Annual Conference of Indian Pharmacological Society; IPSCON-2016, at PGIMER, Chandigarh, 2016.
51. Devendra Pratap Singh S.P.B., Manish Nivsarkar, Quercetin and Quercetin based compositions for preventing or treating Nonsteroidal anti-inflammatory drugs-induced gastroenteropathy. 2016, IN Patent App. 201621021085, http://dx.doi.org/10.13140/RG.2.2.23288.24322.
52. Ganesh, N.S., Bharathi, G., Joshi, H., Jayanthi, C., Singh, D.P., Buoyant multiparticulate drug delivery - a focus on hydrogel beads. World J. Pharm. Pharm. Sci. 2:2 (2013), 450–464.
53. Singh, D.P., Borse, S.P., Nivsarkar, M., Co-administration of quercetin with pantoprazole sodium prevents NSAID-induced severe gastroenteropathic damage efficiently: evidence from a preclinical study in rats. Exp. Toxicol. Pathology 69:1 (2017), 17–26.
54. Singh, D.P., Jayanthi, C., Hanumanthachar, K.J., Pharmaceutical developability of clinically relevant flavonoids like Curcumin: why are we failing?. Med. Clin. Rev., 2017, 10.21767/2471-299X.1000043.
55. Russo, M., et al. The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem. Pharmacol. 83:1 (2012), 6–15.
56. Farzaei, M.H., Abdollahi, M., Rahimi, R., Role of dietary polyphenols in the management of peptic ulcer. World J. Gastroenterology WJG, 21(21), 2015, 6499.
57. Amirchaghmaghi, M., et al. A randomized placebo-controlled double blind clinical trial of quercetin for treatment of oral lichen planus. J. Dent. Res. Dent. Clin. Dent. Prospects, 9(1), 2015, 23.
58. Wu, L.X., et al. Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment. Br. J. Clin. Pharmacol. 73:5 (2012), 750–757.
59. Yang, J.-H., et al. Inhibition of lung cancer cell growth by quercetin glucuronides via G2/M arrest and induction of apoptosis. Drug Metabolism Dispos. 34:2 (2006), 296–304.
60. Cardona, F., et al. Benefits of polyphenols on gut microbiota and implications in human health. J. Nutr. Biochem. 24:8 (2013), 1415–1422.
61. Etxeberria, U., et al. Reshaping faecal gut microbiota composition by the intake of trans-resveratrol and quercetin in high-fat sucrose diet-fed rats. J. Nutr. Biochem. 26:6 (2015), 651–660.
62. Sandoval-Acuña, C., et al. Inhibition of mitochondrial complex I by various non-steroidal anti-inflammatory drugs and its protection by quercetin via a coenzyme Q-like action. Chemico-biological Interact. 199:1 (2012), 18–28.
63. Carrasco-Pozo, C., et al. Differential protective effects of quercetin, resveratrol, rutin and epigallocatechin gallate against mitochondrial dysfunction induced by indomethacin in Caco-2 cells. Chemico-biological Interact. 195:3 (2012), 199–205.
64. Chang, W.-S., et al. Inhibitory effects of flavonoids on xanthine oxidase. Anticancer Res. 13:6A (1992), 2165–2170.
65. Bindoli, A., Valente, M., Cavallini, L., Inhibitory action of quercetin on xanthine oxidase and xanthine dehydrogenase activity. Pharmacol. Res. Commun. 17:9 (1985), 831–839.
66. Pauff, J.M., Hille, R., Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J. Nat. Prod. 72:4 (2009), 725–731.
67. Cotrim, C.A., et al. Quercetin as an inhibitor of snake venom secretory phospholipase A2. Chemico-Biological Interact. 189:1 (2011), 9–16.
68. Lindahl, M., Tagesson, C., Selective inhibition of group II phospholipase A2 by quercetin. Inflammation 17:5 (1993), 573–582.
69. Adibhatla, R.M., Hatcher, J., Phospholipase A 2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic. Biol. Med. 40:3 (2006), 376–387.
70. Hulsmans, M., Holvoet, P., The vicious circle between oxidative stress and inflammation in atherosclerosis. J. Cell. Mol. Med. 14:1–2 (2010), 70–78.
71. Chalimoniuk, M., Secretory phospholipase A2 and its role in oxidative stress and inflammation. Postepy Biochem. 58:2 (2011), 204–208.
72. Chuang, C.-C., et al. Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor-α–mediated inflammation and insulin resistance in primary human adipocytes. Am. J. Clin. Nutr. 92:6 (2010), 1511–1521.
73. Comalada, M., et al. In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-κB pathway. Eur. J. Immunol. 35:2 (2005), 584–592.
74. Jiang, W., et al. Quercetin suppresses NLRP3 inflammasome activation and attenuates histopathology in a rat model of spinal cord injury. Spinal Cord. 54:8 (2016), 592–596.
75. Carlo, G.D., et al. Effects of quercetin on the gastrointestinal tract in rats and mice. Phytotherapy Res. 8:1 (1994), 42–45.
76. Ulluwishewa, D., et al. Regulation of tight junction permeability by intestinal bacteria and dietary components. J. Nutr. 141:5 (2011), 769–776.
77. Boelsterli, U.A., Redinbo, M.R., Saitta, K.S., Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies. Toxicol. Sci. 131:2 (2013), 654–667.
78. Mancini, A., Di Battista, J., The cardinal role of the phospholipase A2/cyclooxygenase-2/prostaglandin E synthase/prostaglandin E2 (PCPP) axis in inflammostasis. Inflamm. Res. 60:12 (2011), 1083–1092.
79. Kumar, P., et al. Effect of Quercetin on lipid peroxidation and changes in lung morphology in experimental influenza virus infection. Int. J. Exp. Pathology 84:3 (2003), 127–134.
80. Becerra-Torres, S.L., et al. The flavonoid quercetin protects and prevents against potassium dichromate–induced systemic peroxidation of lipids and diminution in renal clearance of para-aminohippuric acid and inulin in the rat. Drug Chem. Toxicol. 32:1 (2009), 88–91.
81. Suzuki, T., Hara, H., Quercetin enhances intestinal barrier function through the assembly of zonnula occludens-2, occludin, and claudin-1 and the expression of claudin-4 in Caco-2 cells. J. Nutr. 139:5 (2009), 965–974.
82. Tang, D., et al. Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. Am. J. Respir. cell Mol. Biol. 41:6 (2009), 651–660.
83. Vijayababu, M., et al. Quercetin downregulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3). Mol. Cell. Biochem. 287:1–2 (2006), 109–116.
84. Kang, C.-H., et al. Quercetin inhibits lipopolysaccharide-induced nitric oxide production in BV2 microglial cells by suppressing the NF-κB pathway and activating the Nrf2-dependent HO-1 pathway. Int. Immunopharmacol. 17:3 (2013), 808–813.
85. Mochizuki, M., et al. Effect of quercetin conjugates on vascular permeability and expression of adhesion molecules. Biofactors 22:1–4 (2004), 201–204.
86. Murakami, S., Muramatsu, M., Otomo, S., Inhibition of gastric H+ K+-ATPase by quercetin. J. Enzyme Inhibition 5:4 (1991), 293–298.
87. Lam, J.R., et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. Jama 310:22 (2013), 2435–2442.
88. Corley, D.A., et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 139:1 (2010), 93–101.
89. Richards, J.B., Goltzman, D., Proton pump inhibitors: balancing the benefits and potential fracture risks. Can. Med. Assoc. J. 179:4 (2008), 306–307.
90. Tuskey, A., Peura, D., The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage. Arthritis Res. Ther., 15(Suppl 3), 2013, S6.
91. Reuter, B.K., Davies, N.M., Wallace, J.L., Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 112:1 (1997), 109–117.
92. Attal, N., et al. Behavioural and electrophysiological evidence for an analgesic effect of a non-steroidal anti-inflammatory agent, sodium diclofenac. Pain 35:3 (1988), 341–348.
93. Guideline, P.-B.T., OECD guideline for the testing of chemicals. Hershberger, 2001, 601.
94. Coşkun, Ö., et al. Protective Effects of Quercetin, a Flavonoid Antioxidant, in Absolute Ethanol-induced Acut Gastric Ulcer. 2004.
95. Fornai, M., et al. NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same?. J. Pharmacol. Exp. Ther. 348:1 (2014), 86–95.
96. Mei, Q., et al. A protective effect of melatonin on intestinal permeability is induced by diclofenac via regulation of mitochondrial function in mice. Acta Pharmacol. Sin. 32:4 (2011), 495–502.
97. Atchison, C.R., et al. Drug enterocyte adducts: possible causal factor for diclofenac enteropathy in rats. Gastroenterology 119:6 (2000), 1537–1547.
98. LoGuidice, A., et al. Pharmacologic targeting of bacterial β-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice. J. Pharmacol. Exp. Ther. 341:2 (2012), 447–454.
99. Sivalingam, N., et al. Curcumin attenuates indomethacin-induced oxidative stress and mitochondrial dysfunction. Archives Toxicol. 82:7 (2008), 471–481.
100. Granger, D.N., Kvietys, P.R., Reperfusion injury and reactive oxygen species: the evolution of a concept. Redox Biol. 6 (2015), 524–551.
101. Vaananen, P.M., Meddings, J.B., Wallace, J.L., Role of oxygen-derived free radicals in indomethacin-induced gastric injury. Am. J. Physiology-Gastrointestinal Liver Physiology 261:3 (1991), G470–G475.
102. Parks, D.A., Williams, T.K., Beckman, J.S., Conversion of xanthine dehydrogenase to oxidase in ischemic rat intestine: a reevaluation. Am. J. Physiology-Gastrointestinal Liver Physiology 254:5 (1988), G768–G774.
103. Odabasoglu, F., et al. Gastroprotective and antioxidant effects of usnic acid on indomethacin-induced gastric ulcer in rats. J. Ethnopharmacol. 103:1 (2006), 59–65.
104. Berenguer, B., et al. Protective and antioxidant effects of Rhizophora mangle L. against NSAID-induced gastric ulcers. J. Ethnopharmacol. 103:2 (2006), 194–200.
105. Hashimoto, S., A new spectrophotometric assay method of xanthine oxidase in crude tissue homogenate. Anal. Biochem. 62:2 (1974), 426–435.
106. Nieto, F.J., et al. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?. Atherosclerosis 148:1 (2000), 131–139.
107. Ohkawa, H., Ohishi, N., Yagi, K., Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95:2 (1979), 351–358.
108. Lange, S., Delbro, D., Jennische, E., Evans blue permeation of intestinal mucosa in the rat. Scandinavian J. Gastroenterology 29:1 (1994), 38–46.
109. Watanabe, T., et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin. Gastroenterol. Hepatol. 6:11 (2008), 1279–1282.
110. Lanas, Á., et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin. Gastroenterology Hepatology 13:5 (2015), 906–912 e2.
111. Adebayo, D., Bjarnason, I., Is non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more important than NSAID gastropathy?. Postgrad. Med. J. 82:965 (2006), 186–191.
112. Singh, D.P., Borse, S.P., Nivsarkar, M., Clinical importance of nonsteroidal antiinflammatory drug enteropathy: the relevance of tumor necrosis factor as a promising target. Transl. Res. 175 (2016), 76–91.
113. Matsui, H., et al. The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine. J. Clin. Biochem. Nutr. 48:2 (2011), 107–111.
114. Becker, J.C., Domschke, W., Pohle, T., Current approaches to prevent NSAID-induced gastropathy–COX selectivity and beyond. Br. J. Clin. Pharmacol. 58:6 (2004), 587–600.
115. DiBaise, J.K., et al. Gut microbiota and its possible relationship with obesity. Mayo Clinic Proceedings, 2008, Elsevier.
116. Zhang, H., et al. Host adaptive immunity alters gut microbiota. ISME J. 9:3 (2015), 770–781.
117. Hagiwara, M., et al. Role of unbalanced growth of gram-negative bacteria in ileal ulcer formation in rats treated with a nonsteroidal anti-inflammatory drug. J. Med. Invest 51:1–2 (2004), 43–51.
118. Sivalingam, N., et al. Curcumin reduces indomethacin-induced damage in the rat small intestine. J. Appl. Toxicol. 27:6 (2007), 551–560.
119. Kamanlı, A., et al. Plasma lipid peroxidation and antioxidant levels in patients with rheumatoid arthritis. Cell Biochem. Funct. 22:1 (2004), 53–57.
120. Chao, G., Zhang, S., Therapeutic effects of muscovite to non-steroidal anti-inflammatory drugs-induced small intestinal disease. Int. J. Pharm. 436:1 (2012), 154–160.
121. Groot, H.d., Rauen, U., Tissue injury by reactive oxygen species and the protective effects of flavonoids. Fundam. Clin. Pharmacol. 12:3 (1998), 249–255.
122. Sanchez, M., et al. Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. J. Hypertens. 24:1 (2006), 75–84.
123. Metzler, M., et al. Curcumin uptake and metabolism. Biofactors 39:1 (2013), 14–20.
124. Anand, P., et al. Bioavailability of curcumin: problems and promises. Mol. Pharm. 4:6 (2007), 807–818.
125. Prasad, S., Tyagi, A.K., Aggarwal, B.B., Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res. Treat. 46:1 (2014), 2–18.
126. Graf, B.A., et al. Disposition and metabolism of [2-14C] quercetin-4′-glucoside in rats. Drug Metabolism Dispos. 33:7 (2005), 1036–1043.
127. SuperCYP, SuperCYP. Charité Berlin.
128. O'Leary, K.A., et al. Flavonoid glucuronides are substrates for human liver β-glucuronidase. FEBS Lett. 503:1 (2001), 103–106.
129. Bartholomé, R., et al. Deconjugation kinetics of glucuronidated phase II flavonoid metabolites by β-glucuronidase from neutrophils. Drug metabolism Pharmacokinet. 25:4 (2010), 379–387.
130. Pralhad, T., Rajendrakumar, K., Study of freeze-dried quercetin–cyclodextrin binary systems by DSC, FT-IR, X-ray diffraction and SEM analysis. J. Pharm. Biomed. analysis 34:2 (2004), 333–339.
131. Srinivas, K., et al. Solubility and solution thermodynamic properties of quercetin and quercetin dihydrate in subcritical water. J. Food Eng. 100:2 (2010), 208–218.